首页> 美国卫生研究院文献>International Journal of Hematology-Oncology and Stem Cell Research >A Review on Iron Chelators in Treatment of Iron Overload Syndromes
【2h】

A Review on Iron Chelators in Treatment of Iron Overload Syndromes

机译:铁螯合剂治疗铁超负荷综合征的研究进展

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Iron chelation therapy is used to reduce iron overload development due to its deposition in various organs such as liver and heart after regular transfusion. In this review, different iron chelators implicated in treatment of iron overload in various clinical conditions have been evaluated using more up-to-date studies focusing on these therapeutic agents. Deferoxamine, Deferiprone and Deferasirox are the most important specific US FDA-approved iron chelators. Each of these chelators has their own advantages and disadvantages, various target diseases, levels of deposited iron and clinical symptoms of the afflicted patients which may affect their selection as the best modality. Taken together, in many clinical disorders, choosing a standard chelator does not have an accurate index which requires further clarifications. The aim of this review is to introduce and compare the different iron chelators regarding their advantages and disadvantages, usage dose and specific applications.
机译:铁螯合疗法由于定期输血后沉积在肝脏和心脏等各种器官中而被用于减少铁超负荷的发展。在本综述中,已使用针对这些治疗剂的最新研究评估了涉及在各种临床条件下治疗铁超负荷的不同铁螯合剂。去铁胺,去铁酮和地拉罗司是美国FDA批准的最重要的特定铁螯合剂。这些螯合剂中的每一种都有各自的优缺点,各种目标疾病,铁沉积水平和患病患者的临床症状,这可能会影响他们选择最佳治疗方式。综上所述,在许多临床疾病中,选择标准螯合剂并没有准确的指标,需要进一步澄清。这篇综述的目的是介绍和比较不同的铁螯合剂的优缺点,使用剂量和具体应用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号